Stada Claims A First With Ready-To-Use Bortezomib In Europe
Stada says it is not only first-to-market with generic bortezomib in major European markets. It is also offering a more convenient ready-to-use solution.
You may also be interested in...
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.
Generic versions of Revlimid have been launched in countries across Europe, with Sandoz and Stada among those to have confirmed the introduction of lenalidomide in numerous European markets. Meanwhile, US competition to Revlimid is expected next month.
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.